Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
SUPERNUS PHARMACEUTICALS, INC. (SUPN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K/A Quarterly results
Docs: "Supernus Announces Second Quarter 2023 Financial Results"
08/08/2023 8-K Quarterly results
Docs: "Supernus Announces Second Quarter 2023 Financial Results"
05/09/2023 8-K Quarterly results
Docs: "Supernus Announces First Quarter 2023 Financial Results"
02/28/2023 8-K Quarterly results
Docs: "Supernus Announces Fourth Quarter and Full Year 2022 Financial Results"
11/08/2022 8-K Quarterly results
Docs: "Supernus Announces Third Quarter 2022 Financial Results"
08/04/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
08/04/2021 8-K Quarterly results
Docs: "Supernus Announces Second Quarter 2021 Financial Results"
05/05/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
08/18/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
02/27/2020 8-K Quarterly results
11/06/2019 8-K Quarterly results
Docs: "Supernus Announces Third Quarter 2019 Financial Results and Topline Data from Phase III Study of SPN-810 for Treatment of Impulsive Aggression in ADHD Patients"
08/06/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Supernus Announces First Quarter 2019 Financial Results"
11/06/2018 8-K Quarterly results
Docs: "Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue"
08/07/2018 8-K Quarterly results
Docs: "Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue"
05/08/2018 8-K Quarterly results
Docs: "Supernus Announces First Quarter 2018 Financial Results and Record Quarterly Revenue"
08/02/2017 8-K Quarterly results
Docs: "Supernus Announces Record Second Quarter 2017 Financial Results"
05/09/2017 8-K Form 8-K - Current report
02/28/2017 8-K Form 8-K - Current report
08/02/2016 8-K Form 8-K - Current report
05/03/2016 8-K Quarterly results
Docs: "Supernus Announces First Quarter 2016 Financial Results"
03/02/2016 8-K Quarterly results
Docs: "Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results",
"Supernus to Present at March Cowen Health Care Conference"
11/03/2015 8-K Quarterly results
Docs: "Supernus Announces Third Quarter 2015 Financial Results and Raises 2015 Guidance"
08/04/2015 8-K Quarterly results
Docs: "Supernus Announces Second Quarter 2015 Financial Results"
05/05/2015 8-K Quarterly results
Docs: "Supernus Announces First Quarter 2015 Financial Results"
03/10/2015 8-K Quarterly results
Docs: "Supernus Announces Fourth Quarter and Full Year 2014 Results"
11/12/2014 8-K Quarterly results
Docs: "Supernus Announces Third Quarter 2014 Results",
"Supernus Announces Issuance of Fourth U.S. Patent Protecting Trokendi XR® Rockville, MD, November 7, 2014 - Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a fourth patent by the United States Patent and Trademark Office covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent was issued by the USPTO on November 4, 2014. It provides protection for the product with expiration that is no earlier than 2027. “We are committed to protecting our products with strong intellectual property and to driving sustainable and durable growth for our products. The issuance of this patent expands our proprietary positi..."
08/11/2014 8-K Quarterly results
Docs: "Form of Executive Retention Agreement",
"Amendment to Amended and Restated Employment Agreement, by and between the Company and Jack Khattar",
"Supernus Announces Second Quarter 2014 Results"
05/12/2014 8-K Quarterly results
Docs: "Supernus Announces First Quarter 2014 Results"
03/12/2014 8-K Quarterly results
Docs: "Supernus Announces Fourth Quarter and Full Year 2013 Results",
"Supernus Announces Issuance of Third US Patent Protecting Trokendi XR™ Rockville, MD, March 12, 2014 - Supernus Pharmaceuticals, Inc. , a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced the issuance of a third patent by the United States Patent and Trademark Office covering Trokendi XR™, its novel once-daily extended-release topiramate product. The patent was issued by the USPTO on March 04, 2014. It provides protection for the product with expiration that is no earlier than 2027. “We continue to place great importance on expanding and protecting our intellectual property to ensure the sustainability and longevity of our products. The issuance of this patent provides us with a broadene..."
11/12/2013 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy